The most recently approved vaccine is Bexsero, made by Cambridge, Mass.-based Novartis Vaccines and Diagnostics. The other vaccine, Trumenba, made by Pfizer, received approval in October 2014.
Before the approval of the two vaccines, existing approved meningococcal vaccines in the U.S. only covered four of the five main serogroups of the bacteria causing meningococcal disease, not serogroup B, according to the FDA. The director of the FDA’s Center for Biologics Evaluation and Research called the approvals “a major public health accomplishment toward preventing life-threatening disease.”
Meningococcal disease can be treated with antibiotics, but death or long-term complications are possible even with such treatment. Vaccines are the most effective way to prevent this illness.
More articles on vaccines:
12-year study finds measles vaccine safe, rare adverse effects
Experimental Ebola vaccine by Johnson & Johnson begins trials
Ebola, flu, measles: 7 latest stories on vaccines
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.